QC
ARCT icon

Quadrature Capital’s Arcturus Therapeutics ARCT Stock Holding History

Quadrature Capital’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$87.9K Sell
13,075
-17,003
-57% -$134K ﹤0.01% 1478
2026
Q1 		$232K Buy
+30,078
New +$219K ﹤0.01% 1066

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Quadrature Capital's ARCT Position: Q2 2026 in Review

Quadrature Capital reduced its Arcturus Therapeutics (ARCT) stake by 57% in Q2 2026, selling an estimated $134K and leaving 13,075 shares worth $87.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1478.

Quadrature Capital first reported a position in ARCT in Q1 2026 and has held it in 2 quarters since. The position peaked at $232K in Q1 2026. 135 funds tracked by Wall St. Rank hold ARCT as of Q2 2026.

  • Quadrature Capital held 13,075 shares of Arcturus Therapeutics worth $87.9K as of Q2 2026.
  • Quadrature Capital sold 17,003 Arcturus Therapeutics shares in Q2 2026, an estimated $134K.
  • Arcturus Therapeutics made up ﹤0.01% of Quadrature Capital's portfolio in Q2 2026, its #1478 holding.
  • Quadrature Capital first reported a position in Arcturus Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Quadrature Capital's Arcturus Therapeutics position peaked at $232K in Q1 2026.
  • 135 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.